Founder and Managing Director
Mrs. Bindi Chudgar is one of the most distinguished women in the corporate world. Since inception, Mrs. Chudgar’s entrepreneurial intellect has ensured that Lambda grows both organically and inorganically to become a truly global CRO. Over the years, her progressive vision and values have helped Lambda create a niche to stand apart from the rest in the CRO industry. Meticulous by nature, she overlooks Lambda’s Corporate M&A, Strategy, Finance & Human Resources embracing the best of contemporary and conventional ideologies which are the best fit for the organization globally.
Mrs. Chudgar’s keenness on high-quality standards is best reflected in Lambda’s exceptional regulatory track record. The organization’s various facilities across the world have undergone successful accreditations by some of the world’s topmost regulatory agencies. It is her visionary genius and strong-willed determination that helps Lambda transcend geographical boundaries to excel in the world’s most promising pharmaceutical markets, besides continually augmenting and diversifying its service portfolio and expertise.
Mrs. Chudgar has always been a people’s person. She believes in building an engaging and empowering work culture which are the foundation and key drivers for building a strong and successful organization.
She is determined to continue raising the bar for the development and commercialization of new medical therapies worldwide, through Lambda.
Dr. Tausif Monif
President – Global Operations
Dr Tausif brings with him a rich experience of more than 24 years in the Clinical Research Industry. During his tenure with Ranbaxy and subsequently Sun Pharmaceuticals, he played a pivotal role in the success of the company’s multiple marketing authorizations in the US, EU and RoW markets. He was also in parallel heading their Clinical Operations in Eastern Europe.
He has numerous publications and academic accreditations to his credit and has successfully faced multiple Regulatory Audits across the world in his illustrious career.
His last assignment was as Vice President-Sun Pharmaceuticals heading their Clinical Pharmacology and Pharmacokinetic division globally and played a pivotal role in advancing their New Drug Development portfolio with his varied experience.
Stephanie C. Finnegan
Chief Operating Officer
Stephanie has over 30 years of experience in the pharmaceutical industry and has held leadership positions in the late-phase clinical research sector. Her expertise includes oncology, neurodegenerative diseases and psychology, immunology, infectious diseases, and nephrology. Experience working with innovative compounds, large molecules, and follow-on drugs (including 505b2, ANDA, biosimilars) add value to Novum’s business strategy.
Stephanie brings to Novum a passionate belief in the power of teamwork and a proven track record of successfully growing companies and developing strong teams who are empowered and incentivized to achieve unparalleled personal and professional goals.
VP, Clinical Trials and Data Management
Ms. Gongas has 23 years of experience within the science and clinical medicine fields; 20 years of that experience is with Novum. She has held a wide range of positions with increasing responsibility. In a career spanning cost analysis, project management and study conduct, Ms. Gongas currently has a senior leadership role with Novum. Her understanding of the complexity of clinical research has helped her to direct the management and daily operations of all clinical endpoint studies and data management services. Ms. Gongas helped to establish the one-of-a-kind Novum Clinical Research Associate Academy. In this innovative program, clinical research associates receive structured, comprehensive training in all aspects of clinical research.
Ms. Gongas is a member of the Society of Clinical Research Professionals and the Society of Clinical Research Associates.
Head of Scientific Affairs
Mr. Niraj Shethji has more than 17 years of research experience working at CROs and Pharmaceutical companies, supporting the early and late phase clinical trials. Before joining Novum, Mr. Shethji served at Sun Pharmaceuticals, Pharma Medica Research, Biovail Corp. and Watson Pharmaceuticals (currently Teva) in variety of roles and increasing responsibilities. He joined Novum in Yr. 2011 to provide scientific leadership to the talented team of scientists, technical writers, statisticians and programmers. In addition to his broad experience with the conventional oral dosage forms (solid/liquid), he gained wide-spread exposure to the design and conduct of the biostudies for complex dosage forms such as transdermal, topical (including corticosteroids), injectable, nasal/inhalation, vaginal/rectal products.
Mr. Shethji has hands on experience in developing study designs and protocols for the NDA/ANDA/505b2 submissions, statistical evaluation/presentation of data and generating high-quality study reports. Mr. Shethji’s diverse experience in fields of PK, PD, bioanalysis, biostatistics, efficacy trials and regulatory sciences assists in directing Novum team in day-to-day functions and guiding clients in their development/submission strategies. He has been greatly involved with Novum’s project management in providing the scientific and operational support to meet client’s expectations. Mr. Shethji received Masters of Pharmacy (Pharmacology) and BS in Pharmacy from University of Pune.
Head of Business Development, US Market
Rob has over 20 years of successful Business Development experience in both Early Phase and Late Phase clinical research. He is a highly experienced, highly motivated Life Science Sales professional and Sales Management Leader. Proven track record of top performance in strategic management, account building, new client acquisition and solution providing to clients in the Pharma and Biotech Industry.
He has extensive experience building accounts across a diverse client base of both biopharmaceutical and generic pharmaceutical companies. As an exceptional communicator with a consultative sales style, Rob assists clients from start to finish with their unique projects.